Business Description
Allergy Therapeutics PLC
ISIN : GB00B02LCQ05
Total Employee Number:
576Compare
Compare
Traded in other countries / regions
AGY.UKHHU.GermanyAGYTF.USA IPO Date
2004-10-11Description
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.38 | |||||
Equity-to-Asset | 0.06 | |||||
Debt-to-Equity | 6.3 | |||||
Debt-to-EBITDA | -0.75 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -2.85 | |||||
Beneish M-Score | -3.59 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -52.6 | |||||
3-Year EBITDA Growth Rate | 20.6 | |||||
3-Year EPS without NRI Growth Rate | 27.5 | |||||
3-Year FCF Growth Rate | 36.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 53.42 | |||||
9-Day RSI | 43.39 | |||||
14-Day RSI | 39.51 | |||||
3-1 Month Momentum % | -26.85 | |||||
6-1 Month Momentum % | -33.61 | |||||
12-1 Month Momentum % | -4.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.13 | |||||
Quick Ratio | 0.7 | |||||
Cash Ratio | 0.31 | |||||
Days Inventory | 175.89 | |||||
Days Sales Outstanding | 47.65 | |||||
Days Payable | 145.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -94.9 | |||||
Shareholder Yield % | -1.68 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 52.22 | |||||
Operating Margin % | -59.02 | |||||
Net Margin % | -84.08 | |||||
EBITDA Margin % | -61.89 | |||||
FCF Margin % | -65.02 | |||||
OCF Margin % | -56.77 | |||||
ROA % | -68.33 | |||||
ROIC % | -68.7 | |||||
3-Year ROIIC % | -175.49 | |||||
ROC (Joel Greenblatt) % | -161.66 | |||||
ROCE % | -95 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 6.25 | |||||
PB Ratio | 68.81 | |||||
EV-to-EBIT | -11.23 | |||||
EV-to-EBITDA | -12.61 | |||||
EV-to-Forward-EBITDA | 124.02 | |||||
EV-to-Revenue | 7.81 | |||||
EV-to-Forward-Revenue | 11.87 | |||||
EV-to-FCF | -11.87 | |||||
Price-to-GF-Value | 2.27 | |||||
Price-to-Median-PS-Value | 3.4 | |||||
Earnings Yield (Greenblatt) % | -8.91 | |||||
FCF Yield % | -8.65 | |||||
Forward Rate of Return (Yacktman) % | -4.75 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Allergy Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | 57.294 | ||
| EPS (TTM) (£) | -0.01 | ||
| Beta | 1.5948 | ||
| 3-Year Sharpe Ratio | 0.88 | ||
| 3-Year Sortino Ratio | 2.79 | ||
| Volatility % | 40.05 | ||
| 14-Day RSI | 39.51 | ||
| 14-Day ATR (£) | 0.008476 | ||
| 20-Day SMA (£) | 0.06951 | ||
| 12-1 Month Momentum % | -4.24 | ||
| 52-Week Range (£) | 0.06 - 0.121 | ||
| Shares Outstanding (Mil) | 6,332.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Allergy Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Allergy Therapeutics PLC Stock Events
| Event | Date | Price (£) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2026-12-11 | In 150 days | ||
| Fourth quarter earnings results for 2026 | 2026-12-11 | In 150 days | ||
| Second quarter earnings results for 2026 | 2026-03-31 | 0.11 (+5.00%) | ||
| General meeting for 2025 | 2026-01-29 11:00 | 0.12 (+8.18%) | ||
| Annual report for 2025 | 2025-12-11 | 0.11 (+2.86%) | ||
| Fourth quarter earnings results for 2025 | 2025-12-11 | 0.11 (+2.86%) | ||
| Second quarter earnings results for 2025 | 2025-03-31 | 0.06 (-0.31%) | ||
| General meeting for 2024 | 2024-12-16 | 0.06 (+0.81%) | ||
| Annual report for 2024 | 2024-11-21 | 0.06 (+4.76%) | ||
| Fourth quarter earnings results for 2024 | 2024-11-06 | 0.05 (+8.40%) |
Show
Entries
Allergy Therapeutics PLC Frequently Asked Questions
What is Allergy Therapeutics PLC(LSE:AGY)'s stock price today?
The current price of LSE:AGY is £0.07. The 52 week high of LSE:AGY is £0.12 and 52 week low is £0.06.
When is next earnings date of Allergy Therapeutics PLC(LSE:AGY)?
The next earnings date of Allergy Therapeutics PLC(LSE:AGY) is 2026-12-11 Est..
Does Allergy Therapeutics PLC(LSE:AGY) pay dividends? If so, how much?
Allergy Therapeutics PLC(LSE:AGY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Allergy Therapeutics PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers